



Adverum Biotechnologies to Present at Upcoming Conferences

November 15, 2017

MENLO PARK, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a leading gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today that company executives will present at upcoming conferences in November.

Event: The 29th Annual Piper Jaffray Healthcare Conference
Date: November 28, 2017
Time: 12:10 – 12:30 p.m. ET
Location: New York, NY
Presentation: Amber Salzman, Ph.D., president and chief executive officer

Event: Barclays Gene Editing & Gene Therapy Summit
Date: November 30, 2017
Time: 9:00 – 9:20 a.m. ET
Location: New York, NY
Presentation: Amber Salzman, Ph.D., president and chief executive officer

A live and replay audio webcast of the Piper Jaffray Healthcare Conference presentation will be available from Adverum's website at <http://investors.adverum.com>.

About Adverum Biotechnologies, Inc.

Adverum is a leading gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum's core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.

Adverum Contact:
Leone Patterson
Chief Financial Officer
650-665-7222
lpatterson@adverum.com

Source: Adverum Biotechnologies, Inc.